Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Lymphoma 2Lymphoma, Follicular 1Burkitt Lymphoma 1

Interventions

Rituximab 25Lenalidomide 20Cyclophosphamide 18obinutuzumab 8Vincristine 8Doxorubicin 8Prednisone 7Bendamustine Hydrochloride 7tazemetostat 6ibrutinib 6Biopsy 6venetoclax 5pembrolizumab 5fludarabine 5Specimen Handling 5CT-P10 5fludarabine phosphate 4R-CHOP protocol 4Peripheral Blood Stem Cell Transplantation 4Nivolumab 4Magnetic Resonance Spectroscopy 4Prednisolone 3Etoposide 3tocilizumab 2copanlisib 2axicabtagene ciloleucel 2atezolizumab 2acalabrutinib 2abexinostat 2Whole-Body Irradiation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Follicular × polatuzumab vedotin × Clear all
NCT05410418 2025-12-15

Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma

Washington University School of Medicine

Phase 2 Active not recruiting
34 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡